ONENESS BIOTECH
合一生技股份有限公司
ONENESS BIOTECH is a Taiwan TPEx-listed biotechnology company; its most advanced asset is FB825 (Phase 2; recruiting, Atopic Dermatitis), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| FB825 | — | Phase 2; recruiting | Atopic Dermatitis | Taiwan, United States | 2026-06-15 | Trial registry |
| SNS851 | — | Phase 1; recruiting | Metabolic Disease | Australia | 2026-08-28 | Trial registry |
| SNS812 | — | Phase 2; completed | Mild to Moderate COVID-19 | Taiwan, United States | 2024-09-19 | Trial registry |
Key events
- Business update (company filing)
Related Drugnews articles
No related articles in this language.